Pfizer Limited - Comprehensive FY26 Disclosure: AGM, Financial Results, and BRSR Core

Company Overview and Regulatory Context

Pfizer Limited (BSE: 500680, NSE: PFIZER) has filed comprehensive disclosures comprising its 75th Annual General Meeting notice, Annual Report for FY 2025-26, and Business Responsibility and Sustainability Report (BRSR) Core. These filings are made pursuant to Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI's Master Circular dated January 30, 2026.

Annual General Meeting and Dividend Declaration

The 75th AGM will be held on July 28, 2026 via video conferencing to:

  • Adopt audited financial statements for FY ended March 31, 2026
  • Declare a final dividend of ₹75 per equity share (750%)
  • Re-appoint Mr. P. Rengan as Director
  • Ratify cost auditor remuneration

The board recommended a final dividend of ₹75 per share totaling ₹343.11 crore, with record date of July 17, 2026 and payment on or after August 4, 2026.

Financial Performance Highlights

Revenue Growth: Strong operational performance with revenue from operations at ₹2,519.65 crore (10.4% YoY growth) and net sales of ₹2,377.11 crore (11.7% growth).

Profitability Metrics: Profit before tax (before exceptional items) reached ₹1,024.83 crore (21.5% growth) with EBITDA margin of 35.9%. However, net profit declined to ₹722.43 crore from ₹767.60 crore in FY25, impacted by exceptional items of ₹49.16 crore mainly from personnel separation costs and New Labour Codes impact.

Balance Sheet Strength: Maintained robust financial position with cash and bank balances of ₹3,111 crore, total assets of ₹4,921.88 crore, and remains essentially debt-free with no significant borrowings.

Business and Operational Developments

Product Launches: Successful introduction of Prevenar 20 vaccine (achieved 12.1% market share in pneumococcal vaccines) and Emblaveo anti-infective therapy for multidrug-resistant infections.

Strategic Partnerships: Exclusive marketing and distribution agreement with Cipla Limited for Corex Dx, Corex LS, Dolonex, and Neksium brands, plus technology-enabled distribution partnership with GoApptiv.

Market Leadership: Maintained strong positions across key products - Prevenar 13 (60% private market share), Eliquis (37% market share with 30% YoY growth), and Zavicefta (42% market share in anti-infectives).

Sustainability and ESG Performance

BRSR Core Disclosure: Comprehensive sustainability report assured by Bureau Veritas (India) Private Limited, covering environmental, social, and governance metrics in compliance with SEBI requirements.

Environmental Achievements:

  • 54% reduction in GHG emissions at Goa plant compared to 2019 baseline
  • Zero Waste to Landfill status maintained with 75.49% waste recycling
  • 4,564 kL water recycled and reused in FY26
  • 49% renewable energy usage at manufacturing site

Social Initiatives: CSR expenditure of ₹16.16 crore focused on cancer care, health education, and antimicrobial resistance prevention through partnerships with Americares India Foundation and Tata Cancer Care Foundation, reaching approximately 9 lakh beneficiaries.

Corporate Governance and Compliance

Board Structure: 7 Directors (3 Independent, 1 Non-Executive Non-Independent, 3 Executive) with 4 board meetings held during FY26.

Compliance Status: Full compliance with environmental laws (Water Act, Air Act, Environment Protection Act) with no reported non-compliances.

Assurance Framework: Financial statements audited by B S R & Co. LLP with unqualified opinion, while BRSR Core received reasonable assurance from Bureau Veritas in accordance with ISAE 3000.

Contingencies and Provisions

Tax Matters: Income tax expense of ₹253.24 crore with disputed demands of ₹606.24 crore across assessment years, of which ₹323.03 crore paid under protest.

Regulatory Contingencies: Significant provisions for DPCO matters (₹19.39 crore against ₹120.90 crore contingent liability) and sales tax/VAT litigations (₹4.01 crore against ₹25.75 crore contingent liability).

Employee Benefits: Provisions for gratuity (₹59.71 crore) and compensated absences (₹19.33 crore), with ₹14.06 crore recognized in share-based payment expenses.

Shareholding and Corporate Structure

Ownership Pattern: Promoter holding at 63.92% with public holding of 36.08% out of 4,57,47,732 equity shares, with 99.97% dematerialized.

Subsequent Events: Dividend recommendation subject to shareholder approval at AGM, with no other significant subsequent events requiring adjustment or disclosure.

The comprehensive disclosure demonstrates Pfizer Limited's strong operational performance, commitment to sustainability, and robust corporate governance framework, while acknowledging specific challenges in profitability and ongoing regulatory contingencies.